New cocktail of four drugs shows promise for stubborn myeloma
NCT ID NCT03589222
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing a combination of four drugs—selinexor, bortezomib, dexamethasone, and daratumumab—in 62 patients with multiple myeloma that has returned or not responded to prior treatments. The goal is to see how many patients achieve a significant reduction in cancer. Participants may continue treatment indefinitely if it helps.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
selinexor, bortezomib, dexamethasone, daratumumab
What this could lead to
If successful, this combination could offer a new treatment option for patients with multiple myeloma that has stopped responding to other therapies.
What could go wrong
This is a small, early-phase trial (62 people) with no comparison group. Side effects from the drug combination may be significant, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinica Universitaria de Navarra
Pamplona, Spain
-
Hospital 12 de Octubre
Madrid, Spain
-
Hospital Central de Asturias
Oviedo, Spain
-
Hospital Clinic de Barcelona
Barcelona, Spain
-
Hospital Clinico Universitario de Salamanca
Salamanca, Spain
-
Hospital Clinico de Madrid
Madrid, Spain
-
Hospital Dr Peset
Valencia, Spain
-
Hospital Germans Trials i Pujol
Badalona, Spain
-
Hospital ICO de Girona
Girona, Spain
-
Hospital ICO de L'hospitalet
L'Hospitalet de Llobregat, Spain
-
Hospital Morales Meseguer
Murcia, Spain
-
Hospital Universitario de Canarias
Santa Cruz de Tenerife, Spain
-
Hospital Universitario de Donostia
San Sebastián, Spain
-
Hospital Universitario de Santiago
Santiago de Compostela, Spain
-
Hospital Virgen del Rocio
Seville, Spain